Impact of Drug Resistance on Fluoroquinolone Resistance in Mycobacterium smegmatis
Author Information
Author(s): Zhou Qin, Pu Na, Xu Ge, Liu Hangchi, Jia Xudong, Wang Xiaomin, Xu Peng
Primary Institution: National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People’s Hospital, Shenzhen, Guangdong, China
Hypothesis
Does rifampicin and isoniazid resistance influence fluoroquinolone resistance in Mycobacterium smegmatis?
Conclusion
The study found no evidence that rifampicin and isoniazid resistance directly affects fluoroquinolone resistance in Mycobacterium smegmatis.
Supporting Evidence
- A total of 222 FQs-resistant M.sm strains were selected in vitro from RIF and/or INH resistant M.sm.
- Seven gyrA mutations were detected, with mutations at loci 90 and 94 being the most common.
- There were no differences in FQs resistance developed from RIF and/or INH resistant M.sm.
- The highest resistance to FQs was observed in the Gly88Cys mutant strains.
- M.sm with the identical gyrA mutation showed the highest resistance to ciprofloxacin.
Takeaway
This study looked at how certain drug resistances affect the ability of bacteria to resist other drugs, and found that they don't really influence each other.
Methodology
In vitro experiments were conducted using Mycobacterium smegmatis strains with different drug resistance profiles to assess fluoroquinolone resistance.
Limitations
The study used a model organism, which may not fully represent the complexities of drug resistance in Mycobacterium tuberculosis.
Statistical Information
P-Value
0.004
Confidence Interval
95% CI: 1.67–4.42×10−10
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website